In a strategic push to widen access to next-generation diabetes and weight management therapies, healthcare powerhouse Zydus Lifesciences has partnered with global pharma giant Lupin Limited under a licensing and supply agreement to co-market an innovative semaglutide injection in India.
The deal centers on a patient-friendly, reusable pen device delivering Semaglutide (15 mg/3 ml), a globally recognized therapy for type 2 diabetes and chronic weight management. The collaboration combines Zydus’ drug development expertise with Lupin’s expansive domestic reach, aiming to accelerate availability of advanced treatments for metabolic disorders.
Under the agreement, Lupin secures semi-exclusive co-marketing rights for the therapy under the brands Semanext and Livarise, while Zydus will market it as SEMAGLYN, MASHEMA and ALTERMETA. The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus.
Zydus Managing Director Sharvil Patel emphasized the patient-centric design behind the product: “Our life-changing discoveries are empowering patients to live healthier, more fulfilling lives. Keeping patients’ needs and convenience at the very core, the innovative pen device we are offering is designed to make therapy simpler and improve quality of life. We are pleased to join hands with Lupin to broaden access to this medicine and the novel patient-friendly delivery device, thereby expand its reach across India.”
For Lupin, the partnership strengthens its position in the fast-evolving GLP-1 therapy space.
Managing Director Nilesh Gupta said, "Our partnership with Zydus to market Semaglutide injection in India is a significant step in strengthening our commitment to providing advanced treatment options for cardio-metabolic diseases.
"As GLP 1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs. Together, we aim to expand access to innovative, high-quality treatment options for patients and support healthcare professionals across India.”
Semaglutide is prescribed for adults with inadequately controlled Type 2 Diabetes Mellitus, either as a standalone therapy when metformin is unsuitable or alongside other diabetes medications. It is also indicated for chronic weight management in adults with Obesity or overweight conditions, particularly when accompanied by comorbidities such as hypertension, diabetes, or dyslipidemia.
The alliance comes amid rising demand for GLP-1 therapies worldwide, as drugmakers race to capture a rapidly expanding market driven by increasing rates of diabetes and obesity.
